IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
Background Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to the clinical disease course versus later intervention.Methods and analysis Here we present the ration...
Збережено в:
| Автори: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMJ Publishing Group
2021-09-01
|
| Серія: | BMJ Open |
| Онлайн доступ: | https://bmjopen.bmj.com/content/11/9/e049822.full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|